Related Experiment Videos
Imidazopyrimidines, potent inhibitors of p38 MAP kinase
Kenneth C Rupert1, James R Henry, John H Dodd
1Drug Discovery, Johnson & Johnson Pharmaceutical Research and Development, L.L.C., 1000 Route 202, Raritan, NJ 08869, USA. krupert@prdus.jnj.com
Bioorganic & Medicinal Chemistry Letters
|February 5, 2003
Abstract:
The MAP kinase p38 is implicated in the release of the pro-inflammatory cytokines TNF-alpha and IL-1 beta. Inhibition of cytokine release may be a useful treatment for inflammatory conditions such as rheumatoid arthritis and Crohn's disease. A novel series of imidazopyrimidines have been discovered that potently inhibit p38 and suppress the production of TNF-alpha in vivo.